Medical Monitor
Monopar Therapeutics, Inc.
Pierre Jordaan practiced as an invasive cardiologist at the University of the Free State. He subsequently moved into early phase research and joined an international CRO and was the Principal Investigator in more than 150 studies covering cardiology, pulmonology, ophthalmology, orthopedics, rhumatology and HIV. Relocating to Switzerland as Translational Expert in Cardiovascular Research, he succesfully contributed to the transition of the first Angiotensin Receptor Neprolysin Inhibitor (ARNI), a novel treatment for heart failure, from the preclinic to the clinic.
Thereafter he was a standing member of the Novartis Medical Safety Review Board in addition to primary responsibility overseeing cardiovascular safety during drug development, and more specifically in oncology trials. During this period company-wide cardiac safety monitoring strategies were developed for cardiotoxicity.
More recently Pierre terminated full-time employment to serve as a consultant for cardiovascular safety and as honorary CMO for Mudiro, a Swiss voluntary organisation that promotes healthcare in the remote northeast region of Namibia.
